– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MSA is a progressive ...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
A Kettering family says it will use any means necessary to raise awareness about Multiple System Atrophy, an incurable disease that shuts down bodily functions without warning. “If I can help somebody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results